Payers aim to rein in specialty drug spending
Wall Street Journal (subscription required), March 21, 2008
Due to the rising expenditures for cancer drugs and other high-priced medicines, employers, health plans and pharmacy-benefit managers are increasing efforts to rein in spending. To curb use, payers are pushing for legislation to permit the sale of cheaper versions of biotech drugs. They are also reinforcing rules about trying cheaper therapies first and early certification of patients' prescriptions. Some are even suggesting paying drug companies based on how well a drug works, rather than how much is used.
- Will More Pioneer ACOs Defect?
- Charity HealthCare Conundrum Brewing Among Providers
- Interventional Radiology No Longer a Sub-Specialty
- MU Final Rule Disappoints Some CIOs
- Evidence-Based Practice and Nursing Research: Avoiding Confusion
- NFP Hospitals' Revenue Growth at 'All-Time Low'
- CNO Leads $1M Charge for New Scrubs, Uniforms
- Acute Kidney Injury Gets New Focus
- mHealth Tackles Readmissions
- Transforming Cancer Care